Scientists confirm blood pressure vaccine is in the offing

The usual SOP for an annual check-up is for the doctor to inquire about your family medical history.  Your doctor will likely inquire about the cholesterol and blood pressure of your parents and siblings.  If they have the disease, chances are that you have the condition as well.  Then, you may be required to take a daily medication to control the disease.

But what if a vaccination for high blood pressure is developed? What if there is an injection that could lower your blood pressure?

Seems an unlikely idea, don’t you think?

But a recent study conducted to hypertensive rats had researchers administering 3 needleless injections in a two week interval, according to Hypertension, the journal of the American Heart Association. The lab rats resulted to a lowered blood pressure up to six months and reduced levels of heart and blood vessels damaged. Liver and kidneys also exhibited no ill effects.

According to Hironori Nakagami M.D., Ph.D., the study co-author and a professor at the Osaka University in Japan, in a press release said, “The potential of a vaccine for hypertension offers an innovative treatment that could be very effective for the control of non-compliance which is one of the major problems in the management of hypertensive patients.”

Getting a vaccination shot every six months brings a lower risk for non-compliance than taking their medication every single day.

Current angiotension-converting enzyme or ACE inhibitor blood pressure meds aids blood vessels to relax. This vaccine does something comparable. It targets a hormone which increases blood pressure by triggering constriction of blood vessel, angiotensin II.

It is a DNA vaccine, which means it inserts itself into the body’s DNA. This treatment approach is so new it is not approved for use in humans anywhere in the world.

The World Health Organization says on its website, “Many aspects of the immune response generated by DNA vaccines are not understood. However, this has not impeded significant progress towards the use of this type of vaccine in humans, and clinical trials have begun.”


Leave a Reply

Your email address will not be published. Required fields are marked *